Latest Breaking News On - Robertt keenan - Page 1 : comparemela.com

Sustained Serum Urate Reduction for Gout Patients Observed with AR882

In this data shown at ACR 2023, the URAT1 inhibitor known as AR882 showed promising phase 2b data for patients with gout.

Arthrosi Snags $75M Series D - San Diego Business Journal

AR882 Effectively Lowers Serum Urate Levels in Patients With Gout

After 12 weeks of treatment, the median sUA levels of patients with gout were reduced from 8.6 mg/dL to 3.6 mg/dL in the AR882 75 mg cohort and 5.0 mg/dL in the AR882 50 mg group.

ARTHROSI COMPLETES AR882 PHASE 2B STUDY ENROLLMENT

/PRNewswire/ Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced the completion of enrollment for its global Phase 2b.

ARTHROSI COMPLETES AR882 RENAL IMPAIRMENT STUDY

/PRNewswire/ Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company focused on treatment for the management of gout, today announced the.